NASDAQ:GERN - Geron Corporation
$1.42
 $-0.00
-0.21%
1:35PM EDT
2019-02-15
Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. Janssen is engaged in the development of Imetelstat with two clinical trials, such as a Phase II trial in myelofibrosis (MF), referred to as IMbark, and a Phase II/III trial in myelodysplastic syndromes (MDS) referred to as IMerge. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the RNA template of telomerase, thereby directly inhibiting telomerase activity. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  GERN     avg for
industry  
  avg for
sector  
42 stocks weight:  32. 59   0. 00   0. 00  
42 stocks rank:  3. 24 K 1. 86 K 1. 09 K
# analyst opinions:  1. 00   14. 92   14. 43  
mean recommendation:  2. 50   1. 91   1. 93  

quick ratio:  37. 41   5. 37   1. 81  
current ratio:  37. 80   5. 69   2. 19  

target price low:  3. 25   88. 97   117. 82  
target price avg:  3. 25   115. 19   141. 96  
target price high:  3. 25   143. 40   163. 16  
1-yr high:  6. 38   124. 30   142. 77  
last close:  1. 42   101. 85   127. 84  
50-day avg:  1. 19   98. 27   122. 46  
200-day avg:  2. 86   99. 72   122. 70  
1-yr low:  0. 98   78. 19   100. 16  
volume:  1. 67 M 2. 38 M 4. 64 M
50-day avg volume:  3. 45 M 3. 31 M 4. 94 M
200-day avg volume:  5. 46 M 3. 23 M 4. 28 M

1-day return:  -1. 39 % 0. 22 % 0. 48 %
this week return:  9. 23 % 1. 77 % 2. 01 %
12-wk return:  -7. 19 % 6. 56 % 3. 33 %
52-wk return:  -41. 82 % -2. 23 % 14. 35 %

enterprise value (EV):  75. 90 M 55. 17 B 104. 51 B
market cap:  264. 60 M 49. 01 B 96. 46 B
EBITDA:  -29. 21 M 4. 82 B 7. 18 B
enterprise multiple (EV/EBITDA):  -2. 60   -91. 79   2. 29  
enterprise/revenue (EV/R):  86. 06   29. 84   23. 39  
total revenue:  882. 00 K 11. 28 B 40. 22 B
total debt:  0. 00   13. 73 B 16. 57 B
net income (common):  -27. 15 M 2. 37 B 3. 58 B

shares outstanding:  186. 35 M 607. 99 M 1. 22 B
shares:  185. 40 M 605. 53 M 1. 15 B
shares short:  35. 70 M 11. 62 M 12. 55 M
shares short prior month:  36. 50 M 11. 95 M 13. 44 M
short ratio:  10. 94   4. 82   3. 10  
total cash/share:  0. 89   12. 02   11. 46  
total cash:  166. 35 M 7. 41 B 7. 37 B
free cash flow:  -13. 67 M 95. 99 M 2. 04 B
operating cash flow:  -22. 39 M 164. 74 M 3. 04 B

book value:  0. 98   14. 43   28. 26  
price/book:  1. 44   -1. 57   -2. 97  
gross profits:  -7. 37 M 8. 28 B 18. 09 B
operating margins:  -3318. 59 % -458. 01 % -642. 83 %
EBITDA margins:  0. 00 % 13. 81 % 22. 47 %
profit margins:  0. 00 % 6. 57 % 9. 92 %
gross margins:  0. 00 % 49. 33 % 54. 53 %

1-yr max volatility:  -62. 92 % --- ---
1-yr mean volatility:  0. 13 % 0. 01 % 0. 06 %

1-yr EPS:  -0. 16   3. 03   4. 09  
forward EPS:  -0. 22   4. 33   6. 99  
P/E:  -8. 66   6. 11   26. 91  
forward P/E:  -5. 91   8. 38   10. 48  
PE/G:  -7. 22   0. 37   5. 61  
growth:  1. 20 % 683. 72 % 104. 79 %
earnings high:  -0. 04   1. 27   1. 66  
earnings avg:  -0. 04   1. 01   1. 53  
earnings low:  -0. 04   0. 76   1. 40  
revenue high:  200. 00 K 2. 86 B 11. 19 B
revenue avg:  200. 00 K 2. 78 B 10. 84 B
revenue low:  200. 00 K 2. 67 B 10. 64 B
return on assets:  -12. 11 % -3. 27 % 3. 81 %
return on equity:  -18. 61 % 107. 48 % 27. 82 %
revenue growth:  1. 20 % 648. 36 % 97. 70 %
revenue/share:  0. 01   14. 68   59. 83  

beta (1yr vs S&P500):  1. 30   1. 21   0. 93  
sharpe (1yr):  0. 29   0. 06   0. 98  

held % insiders:  0. 48 % 6. 46 % 3. 21 %
held % institutions:  31. 78 % 79. 10 % 70. 01 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-14 : GERN
.    + 1.028 =         1.028 :: INITIAL WEIGHT
.  + 290.828 =       291.856 :: inverse volume-to-price addition
.  + 186.082 =       477.938 :: spline projection addition
.  - 201.441 =       276.497 :: poor performance penalty
.    x 0.776 =       214.427 :: one-year gains+dividend factor
.    x 9.465 =      2029.513 :: 13 weeks' performance factor
.    x 1.492 =      3029.026 :: industry recommendation factor
.    x 1.642 =      4972.427 :: symbol recommendation factor
.    x 1.884 =      9369.571 :: EV/R factor
.    x 0.999 =      9358.226 :: return on assets factor
.    x 0.998 =      9340.811 :: return on equity factor
.    x 2.194 =     20498.289 :: revenue growth factor
.    x 5.326 =    109174.486 :: current ratio factor
.    x 1.014 =    110663.406 :: quick ratio factor
.    x 1.045 =    115610.568 :: short ratio factor
.    x 2.014 =    232887.806 :: price-to-book factor
.    x 1.131 =    263484.782 :: 5-day avg > 50-day avg
.    x 2.119 =    558314.349 :: P/E weight
.     x 0.61 =    340653.595 :: PE/G factor
.    x 1.592 =    542451.533 :: beta factor
.    x 0.285 =    154824.648 :: sharpe factor
.    x 2.294 =    355223.582 :: target low factor
.    x 1.378 =    489642.967 :: target mean factor
.    x 1.114 =    545228.388 :: target high factor
.    x 1.066 =    581002.353 :: industry 12-weeks return
.    x 0.942 =    547236.568 :: "drift" penalty 4 days ago
.    x 0.999 =    546752.416 :: overall "drift" factor
.    x 0.997 =    545250.127 :: largest single-day jump factor
.    x 0.063 =     34597.089 :: low price factor
.      x 1.0 =     34599.412 :: factor hist industry gain for week 06
.   cubeRoot =        32.585 :: reduced for readability
.                     32.585 :: FINAL WEIGHT for NASDAQ:GERN


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org